Page 228 - Read Online

Douhara et al. DAA therapy for patients with CHC

each case as medical care. in a chronic hepatitis C patient receiving pegylated interferon and
ribavirin therapy. Hepatol Res 2013;43:801-7.
Ethics approval 12. Hung CH, Lee CM, Lu SN, Wang JH, Hu TH, Tung HD, Chen CH,
Chen WJ, Changchien CS. Long-term effect of interferon alpha-
This study conforms to the ethical guidelines of the 2b plus ribavirin therapy on incidence of hepatocellular carcinoma
Helsinki Declaration. The approved number of the in patients with hepatitis C virus-related cirrhosis. J Viral Hepat
institutional review board (IRB) is 72. 2006;13:409-14.
13. Velosa J, Serejo F, Marinho R, Nunes J, Glória H. Eradication of
REFERENCES hepatitis C virus reduces the risk of hepatocellular carcinoma in
patients with compensated cirrhosis. Dig Dis Sci 2011;56:1853-61.
14. Floreani A, Baldo V, Rizzotto ER, Carderi I, Baldovin T, Minola E.
1. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales Pegylated interferon alpha-2b plus ribavirin for naive patients with
FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin HCV-related cirrhosis. J Clin Gastroenterol 2008;42:734-7.
A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic 15. Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnù L, Mazzella
hepatitis C virus infection. N Engl J Med 2002;347:975-82. G, Ascione A, Santantonio T, Piccinino F, Andreone P, Mangia A,
2. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Gaeta GB, Persico M, Fagiuoli S, Almasio PL; Italian Association of
Y. Eradication of hepatitis C virus infection and the development of the Study of the Liver Disease (AISF). Sustained virological response
hepatocellular carcinoma: a meta-analysis of observational studies. to interferon-alpha is associated with improved outcome in HCV-
Ann Intern Med 2013;158:329-37. related cirrhosis: a retrospective study. Hepatology 2007;45:579-87.
3. Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka 16. Hisaka T, Yano H, Ogasawara S, Momosaki S, Nishida N, Takemoto
O, Kuroki T, Nishiguchi S, Sata M, Yamada G, Fujiyama S, Yoshida Y, Kojiro S, Katafuchi Y, Kojiro M. Interferon-alphaCon1 suppresses
H, Omata M. Histologic improvement of fibrosis in patients with proliferation of liver cancer cell lines in vitro and in vivo. J Hepatol
hepatitis C who have sustained response to interferon therapy. Ann 2004;41:782-9.
Intern Med 2000;132:517-24. 17. Izumi N, Asahina Y, Kurosaki M, Yamada G, Kawai T, Kajiwara
4. Cammà C, Di Bona D, Schepis F, Heathcote EJ, Zeuzem S, Pockros E, Okamura Y, Takeuchi T, Yokosuka O, Kariyama K, Toyoda
PJ, Marcellin P, Balart L, Alberti A, Craxì A. Effect of peginterferon J, Inao M, Tanaka E, Moriwaki H, Adachi H, Katsushima S, Kudo
alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of M, Takaguchi K, Hiasa Y, Chayama K, Yatsuhashi H, Oketani M,
individual patient data. Hepatology 2004;39:333-42. Kumada H. Inhibition of hepatocellular carcinoma by PegIFNα-2a in
5. Poynard T, McHutchison J, Manns M, Myers RP, Albrecht J. patients with chronic hepatitis C: a nationwide multicenter cooperative
Biochemical surrogate markers of liver fibrosis and activity in a study. J Gastroenterol 2013;48:382-90.
randomized trial of peginterferon alfa-2b and ribavirin. Hepatology 18. Cheung MC, Walker AJ, Hudson BE, Verma S, McLauchlan J,
2003;38:481-92. Mutimer DJ, Brown A, Gelson WT, MacDonald DC, Agarwal K,
6. Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Foster GR, Irving WL; HCV Research UK. Outcomes after successful
Balart L, Reindollar R, Reddy RK, Wright TL, Lin A, Hoffman J, De direct-acting antiviral therapy for patients with chronic hepatitis C and
Pamphilis J. Peginterferon alfa-2a in patients with chronic hepatitis C decompensated cirrhosis. J Hepatol 2016;65:741-7.
and cirrhosis. N Engl J Med 2000;343:1673-80. 19. ANRS collaborative study group on hepatocellular carcinoma (ANRS
7. Kumada H, Suzuki Y, Ikeda K, Toyota J, Karino Y, Chayama K, CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts). Lack
Kawakami Y, Ido A, Yamamoto K, Takaguchi K, Izumi N, Koike of evidence of an effect of direct-acting antivirals on the recurrence of
K, Takehara T, Kawada N, Sata M, Miyagoshi H, Eley T, McPhee F, hepatocellular carcinoma: data from three ANRS cohorts. J Hepatol
Damokosh A, Ishikawa H, Hughes E. Daclatasvir plus asunaprevir for 2016;65:734-40.
chronic HCV genotype 1b infection. Hepatology 2014;59:2083-91. 20. Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P,
8. Soota K, Maliakkal B. Ribavirin induced hemolysis: a novel Foschi FG, Lenzi M, Mazzella G, Verucchi G, Andreone P, Brillanti
mechanism of action against chronic hepatitis C virus infection. S. Early occurrence and recurrence of hepatocellular carcinoma in
World J Gastroenterol 2014;20:16184-90. HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol
9. Kim SK, Kim SR, Imoto S, Kim CW, Hayashi Y. Sudden-onset 2016;65:727-33.
sarcoidosis with severe dyspnea developing during pegylated 21. Reig M, Mariño Z, Perelló C, Iñarrairaegui M, Ribeiro A, Lens S,
interferon and ribavirin combination therapy for chronic hepatitis C. Díaz A, Vilana R, Darnell A, Varela M, Sangro B, Calleja JL, Forns
Turk J Gastroenterol 2017;28:75-6. X, Bruix J. Unexpected high rate of early tumor recurrence in patients
10. Buss G, Cattin V, Spring P, Malinverni R, Gilliet M. Two cases of with HCV-related HCC undergoing interferon-free therapy. J Hepatol
interferon-alpha-induced sarcoidosis Koebnerized along venous 2016;65:719-26.
drainage lines: new pathogenic insights and review of the literature of 22. Kobayashi M, Suzuki F, Fujiyama S, Kawamura Y, Sezaki H, Hosaka
interferon-induced sarcoidosis. Dermatology 2013;226:289-97. T, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kumada H.
11. Joshita S, Shirahata K, Yazaki Y, Okaniwa S, Nakamura Y, Kimura Sustained virologic response by direct antiviral agents reduces the
T, Noami S, Horigome R, Yagi H, Ito N, Yamazaki A, Akahane Y, incidence of hepatocellular carcinoma in patients with HCV infection.
Umemura T, Yoshizawa K, Tanaka E, Ota M. Cutaneous sarcoidosis J Med Virol 2017;89:476-83.

220 Hepatoma Research ¦ Volume 3 ¦ October 17, 2017